Systematically Testing the Evidence on Marijuana

This research study is being done to determine whether treatment with L- Dihydroxyphenylserine (L-DOPS) versus placebo (an inactive substance that looks like study drug) in addition to other Parkinson Disease (PD) drugs will improve balance, walking, and reduce risk of falls and/or severity of falls in PD subjects. The study is also being done to determine the effectiveness, safety, and tolerability of L-DOPS, and whether it will decrease Freezing of Gait (FOG), improve apathy (generalized disinterest) or show a relationship between apathy and slowed movement and fall risk.

First Posted: June 24, 2016

Condition(s): Parkinson Disease

Intervention(s): L-DOPS, Placebo

Status: Active, not recruiting

Enrollment (expected or actual): 20

Allocation: Randomized

Sponsor: St. Joseph's Hospital and Medical Center, Phoenix

Principal Investigator: Pam Dewey, Research Manager

Completion Date (primary or actual): June 2019

CT.gov Identifier: NCT02812147

the investigators hypothesise that 18F-FDOPA PET kinetic parameters are good biomarkers to characterise suspected LGG brain lesions that exhibit no contrast on MRI, for identifying aggressive lesions. These parameters could constitute diagnostic biomarkers for this indication. This new diagnostic tool could enhance patient care in the short term in an evolving pathology affecting socially active subjects with a poor prognosis

First Posted: August 23, 2022

Condition(s): Glioma

Intervention(s): PET/CT with 18F-DOPA

Status: Recruiting

Enrollment (expected or actual): 88

Allocation: N/A

Sponsor: Central Hospital, Nancy, France

Principal Investigator: Antoine VERGER, MD, PhD

Completion Date (primary or actual): December 12, 2025

CT.gov Identifier: NCT05512403

The purpose of this study is to determine whether Tolcapone crosses from the blood stream into the fluid around the brain and stabilizes the protein that makes leptomeningeal amyloid. Tolcapone is a commercially available generic drug that treats Parkinson's disease. The Investigator plans to evaluate Tolcapone as a treatment for ATTR (Transthyretin Amyloidosis), a rare genetic disease often causing death within 5-15 years after diagnosis. ATTR is characterized by deposition of misfolded protein known as amyloid, in one or more organ systems (including the peripheral and autonomic nervous systems, the heart, the brain and the eyes). The age at which symptoms begin to develop varies widely ranging between 20 to 70 years old. ATTR is progressive, and some variants can have a fatal outcome within a few years of presentation. Treatment options include supportive and symptomatic care that may slow or stop progressive decline in functional state but do not alter the pathological process. Liver transplant can be performed in selected patients but is limited by organ supply, requires lifelong immunosuppression, and may be complicated by progressive heart and nerve amyloid deposition. Importantly, liver transplant does not alter the natural course of central nervous system amyloid disease. To date, no treatment for ATTR penetrates the CNS. At present there is no FDA approved treatment for ATTR amyloidosis in the US. In Europe, Tafamidis has been approved for treatment of stage 1 ATTR-polyneuropathy since 2012. Tafamidis and Tolcapone bind to the thyroxine binding site of TTR (with different drug-transthyretin interactions) and in so doing stabilizes the tetrameric form of TTR, preventing dissociation and amyloid fibril formation The preclinical and clinical data from a variety of experimental systems support the therapeutic activity of TOLCAPONE in TTR mediated disease.

First Posted: July 19, 2018

Condition(s): Transthyretin Amyloidosis, Amyloidosis, Leptomeningeal, Transthyretin-Related

Intervention(s): Tolcapone

Status: Completed

Enrollment (expected or actual): 10

Allocation: N/A

Sponsor: Boston University

Principal Investigator: John L. Berk, Associate Professor,Dept of Medicine, Amyloidosis Center

Completion Date (primary or actual): April 26, 2019

CT.gov Identifier: NCT03591757

Studies in patients with disorders of consciousness (DOC) after severe brain injury implicate dysfunction of the anterior forebrain mesocircuit dysfunction a key underlying mechanism. The anterior forebrain metabolism in DOC is markedly downregulated across brain regions underpinning highly elaborated cognitive behaviors demonstrating a collapse of the level of synaptic background activity required for consistent goal-directed behavior and arousal regulation. Since dopamine levels are one of the primary controllers of the level of synaptic background activity within these forebrain structures and in regulating excitatory glutamatergic homeostasis, the investigators propose to investigate the specific contribution of presynaptic dopamine function in glutamatergic neurotransmission in posttraumatic DOC. The aim of the present study is to measure metabotropic glutamate receptors 5 occupancy in the main gutamatergic structures of the brain using (3-[18F]fluoro-5-(2-pyridinylethynyl)benzonitrile)-positron emission tomography ( [18F]FPEB-PET) at rest and following a short pharmacological challenge with amantadine, an N-methyl-D-aspartate receptor (NMDA-R) antagonist, following L-DOPA, and amantadine + L-DOPA. Using this novel technique in DOC the investigators will characterize the relevance of a presynaptic deficiency to synthesize and/or release dopamine in the final regulation of excitatory interneurons of the anterior forebrain mesocircuit. It is unknown whether glutamatergic neurotransmission is affected across the population of subjects with DOC and, if this condition is secondary to a presynaptic dopaminergic failure of the anterior forebrain mesocircuit (i.e., down-regulation). Since the investigators previously identified the existence of a presynaptic dopaminergic deficit in these subjects due to a failure in the biosynthesis of dopamine, the investigators will evaluate if by providing the main biological substrate of the biosynthesis process (i.e., L-DOPA) the glutamatergic system regains homeostasis. The investigators therefore propose to investigate patients with posttraumatic DOC using [18F]FPEB-PET at rest and following short pharmacological challenges aimed at increasing glutamate and dopamine release.

First Posted: January 28, 2020

Condition(s): Disorder of Consciousness, Traumatic Brain Injury

Intervention(s): Amantadine + L-DOPA, NMDA blocker

Status: Suspended

Enrollment (expected or actual): 30

Allocation: Non-Randomized

Sponsor: Weill Medical College of Cornell University

Principal Investigator:

Completion Date (primary or actual): May 30, 2023

CT.gov Identifier: NCT04244058

Roux-en-Y hepaticojejunostomy is the standard procedure used by most hepatobiliary surgeons for biliary reconstruction following iatrogenic bile duct injury, benign and malignant CBD strictures, choledochal cysts and biliary tract tumors management. The incidence of anastomotic stricture following hepaticojejunostomy in experienced centers ranges between 5%-22%. Hepaticojejunostomy stricture is a serious complication of biliary surgery, if untreated, can lead to repeated cholangitis, intrahepatic stones formation, biliary cirrhosis, hepatic failure and eventually death. Revision of hepaticojejunostomy is a complex procedure, the surgical procedure being made difficult by the sequelae of long-standing unrelieved biliary obstruction like portal hypertension due to secondary biliary cirrhosis, atrophy of liver lobes and presence of cholangiolytic liver abscess. Endoscopic management is not only the least invasive but also very effective via either balloon dilatation or stenting of the stricture. In patients with "Roux-en-Y" hepaticojejunostomy, the endoscopic access to the anastomosis is hampered by the distance traveled by the jejunal loop until reaching the angle of the enteral anastomosis. Many modifications of hepaticojejunostomy to provide permanent endoscopic access have been described in the literature including duodenal, gastric and subcutaneous access loops. Gastric access loop was first described by Sitaram et al. Ten patients had undergone gastric access loop. Access loop was entered easily with the gastroscope in five patients in whom it was attempted. In a series with 16 cases, Hamad MA and El-Amin H assessed different construction of gastric access loop in the form of bilioenterogastrostomy the overall success rate of endoscopic access to the HJ through the three types of BEG was 87.5%, while it was 100% for BEG type III, which is a construction similar to the previous series (BEG) type. Subcutaneous loop access was described by Chen et al. and by Huston et al. In Hutson's series of 7 patients, recurrent strictures were treated with repeated balloon dilations. The stone extractions were all successful. In most series, the subcutaneous loop was used for management os HJ stricture and intrahepatic stones by radiologic intervention. Recently the subcutaneous loop can be used as an endoscopic biliary access.

First Posted: August 17, 2017

Condition(s): Jaundice, Obstructive

Intervention(s): hepaticojejunostomy, modified hepaticojejunostomy with subcutaneous access loop, modified hepaticojejunostomy with gastric access loop

Status: Not yet recruiting

Enrollment (expected or actual): 30

Allocation: Randomized

Sponsor: Assiut University

Principal Investigator: Mohamad Raafat, Assistant lecturer at General surgery department

Completion Date (primary or actual): December 1, 2019

CT.gov Identifier: NCT03252379

The investigators are seeking healthy volunteers and people with schizophrenia or schizoaffective disorder for a clinical study of the immune system in psychotic disorders. This is an observational study, to understand the ways in which the immune system may be contributing to the disease process.

First Posted: November 5, 2021

Condition(s): Schizophrenia, Schizo Affective Disorder, Schizophreniform Disorders

Intervention(s): SCID (Standardized Clinical Interview for DSM-V), PSS (Perceived Stress Score), Urine Toxicology Screen, Vitals, Blood Work, PQ-B, COVID Screening, Positive and Negative Syndrome Scale (PANSS)

Status: Recruiting

Enrollment (expected or actual): 100

Allocation:

Sponsor: Stanford University

Principal Investigator: Agnieszka Kalinowski, Clinical Instructor

Completion Date (primary or actual): August 31, 2023

CT.gov Identifier: NCT05109065

The proposed project seeks to demonstrate the engagement of post-exposure dopamine neurotransmission and downstream acute reorganization of dopaminergic resting-state neural networks as a means of increasing consolidation of extinction memories formed during analogue exposure therapy in adult women with PTSD. Participants will include 120 women aged 21-50 with a current diagnosis of PTSD related to physical or sexual assault, English speaking, and medically healthy. Participants will complete the stages of the study across 2-3 days, depending on participant need.

First Posted: September 22, 2020

Condition(s): PTSD, Post Traumatic Stress Disorder

Intervention(s): L-DOPA, Placebo

Status: Recruiting

Enrollment (expected or actual): 120

Allocation: Randomized

Sponsor: University of Wisconsin, Madison

Principal Investigator:

Completion Date (primary or actual): December 2023

CT.gov Identifier: NCT04558112

Endoscopic retrograde cholangiopancreatography (ERCP) is commonly performed to remove bile duct stones.Endoscopic sphincterotomy (EST), endoscopic papillary balloon dilation (EPBD), and endoscopic sphincterotomy plus balloon dilation (sEST+EPBD) are 3 methods used to enlarge the papillary orifice, but their efficacy and safety remains controversial. This study aimed to compare these methods for treating common bile duct (CBD) stones.

First Posted: January 31, 2018

Condition(s): ERCP

Intervention(s): Erbao electric knife, Three-cavity incision knife, Columnar expansion balloon

Status: Enrolling by invitation

Enrollment (expected or actual): 450

Allocation: Randomized

Sponsor: Zhujiang Hospital

Principal Investigator:

Completion Date (primary or actual): September 1, 2021

CT.gov Identifier: NCT03416205

The primary objective of the study is to obtain preliminary safety and tolerability data with davunetide (NAP, AL-108) in patients with a tauopathy (frontotemporal lobar degeneration [FTLD] with predicted tau pathology, corticobasal degeneration syndrome [CBS] or progressive supranuclear palsy [PSP]). The secondary objectives of this study are to obtain preliminary data on short term changes (at 12 weeks) in a variety of clinical, functional and biomarker measurements from baseline, including cerebrospinal fluid (CSF) tau levels, eye movements, and brain MRI measurements.

First Posted: January 26, 2010

Condition(s): Predicted Tauopathies, Including, Progressive Supranuclear Palsy, Frontotemporal Dementia With Parkinsonism Linked to Chromosome 17, Corticobasal Degeneration Syndrome, Progressive Nonfluent Aphasia

Intervention(s): davunetide (AL-108, NAP), Placebo nasal spray

Status: Completed

Enrollment (expected or actual): 12

Allocation: Randomized

Sponsor: University of California, San Francisco

Principal Investigator: Adam Boxer, Associate Professor

Completion Date (primary or actual): December 2012

CT.gov Identifier: NCT01056965

The present protocol is designed to conduct nutrigenomic and nutrigenetic studies on foods conforming to the Mediterranean diet, in order to determine the effect functional foods have on blood parameters (cholesterol metabolism, glucose metabolism, hepatic function, inflammation, nutritional status) and body composition in the context of four different diets (standard, high fat, high protein, low carbohydrate). The study focuses on the effect of these nutraceutical foods in relation to different diets. Diets were chosen to reflect the standard reference diets used by the general population, so as the outcomes of the addition of each interventional food element may be interpreted in the context of a variety of dietary patterns.

First Posted: July 1, 2013

Condition(s): Obesity

Intervention(s): Hazelnuts, Chocolate, Red wine, Olive Oil, Wild mixed greens, Chestnut, No Dietary Supplement

Status: Recruiting

Enrollment (expected or actual): 50

Allocation: Randomized

Sponsor: University of Rome Tor Vergata

Principal Investigator: LAURA DI RENZO, Professor of Human Nutrition

Completion Date (primary or actual): January 2016

CT.gov Identifier: NCT01890070

Systemic Sclerosis (SSc) is an autoimmune connective tissue disease characterized by autoantibodies, fibrosis and microvascular injury and endothelial cell activation that results in vascular damage. Vascular injury induces both innate and acquired immune responses resulting in fibroblast activation and organ fibrosis. SSc may target multiple organs, including: skin, lungs, heart, vascularization, kidneys, the gastrointestinal tract and musculoskeletal structures. Mortality among scleroderma patients is significant, with a 3.5 standardized mortality ratio (SMR) in studies of prevalent cases. This mortality may be increased in the early years of the disease, reaching a SMR of 4 in a multinational inception cohort. In general, treatment strategies target involved organs as early as possible to avoid damage. Many treatment options are available for each manifestation, but evidence with respect to the order of treatment is scarce. Financial costs, the lack of proper outcome measures, difficulty to recruit patients as a rare disease, all prevent the development of new big clinical trials, oppositely to other common diseases such as stroke or cancer. The heterogeneous features of SSc may make trials challenging. The current guidelines available are the British guidelines (2017) , and the updated European League Against Rheumatism (EULAR) guidelines, published in 2017. Management guidelines have some gaps regarding second-line treatment, combinations and there are no proposed algorithms. With the pragmatic trials, the investigators intend to fill the gap between the complicated randomized clinical trials and the observational studies. Using the treatments that have already been proved useful in SSc, in an open-label randomized way and based on some refined expert-made algorithms, will allow the investigators to establish the order in how to use them. Patients will be offered to participate with the collection of their clinical data and, if they give their consent, they will be randomized according to the algorithms. There will be an optional part of the study consisting in the collection of blood samples and skin samples for future research.

First Posted: August 1, 2018

Condition(s): Scleroderma, Systemic, Sclerosis, Systemic

Intervention(s): Interstitial lung disease induction algorithm, Pulmonary arterial hypertension algorithm, Raynaud's phenomenon algorithm, Digital ulcer algorithm, Inflammatory arthritis algorithm, Gastroesophageal reflux algorithm, Bacterial overgrowth algorithm, Constipation algorithm, Skin involvement algorithm, Pain algorithm

Status: Not yet recruiting

Enrollment (expected or actual): 400

Allocation: Randomized

Sponsor: University of West London

Principal Investigator: Andreu Fernandez Codina, Principal investigator

Completion Date (primary or actual): October 2021

CT.gov Identifier: NCT03610217

The purpose of this research is to use 18 F Fluorodopa positron emission tomography (FDOPA PET) to measure dopamine function, and utilize magnetic resonance imaging (MRI) to measure inflammatory and oxidative stress markers in persons with Parkinson's disease. The overall goal of this study will be to further the understanding of the effects of a novel meditation technique called orgasmic meditation (OM) on these neurophysiological parameters.

First Posted: November 2, 2021

Condition(s): Parkinson Disease, Idiopathic Parkinson Disease

Intervention(s): [F-18] Fluorodopa Positron Emission Tomography, OM Meditation

Status: Not yet recruiting

Enrollment (expected or actual): 80

Allocation: Randomized

Sponsor: Andrew Newberg

Principal Investigator: Andrew Newberg, Professor, Department of Integrative Medicine and Nutritional Sciences; Professor, Department of Radiology

Completion Date (primary or actual): June 1, 2025

CT.gov Identifier: NCT05103618

This project will use the experimental medicine approach of a Phase IIa Proof of Mechanism 16-week, randomized, double-blind, controlled trial of L-DOPA versus placebo administration in combination with a 16 week social skills training group in order to: 1) identify differences in social reward processes in adolescent and young adult ASD participants versus healthy controls as measured by fMRI activation in reward circuitry; 2) provide evidence of dopaminergic moderating effects on social reward components in ASD with greater pre- to post-treatment changes expected in the subjects randomized to L-DOPA versus placebo; 3) examine the hypothesis that baseline readouts of putative dopamine signaling (wanting activation responses) will predict the extent of fMRI reward-related activation changes pre- to post-treatment; and, 4) examine the proposed relationship between pre- to post- L-DOPA fMRI reward changes and changes in individual self-report ratings of social wanting and ratings of videotaped positive affect in a structured interaction with an examiner. The study will enroll 56 participants with DSM-5 ASD between the ages of 13-30 years of age and 18 healthy control participants without histories of psychopathology for baseline comparisons.

First Posted: August 9, 2017

Condition(s): ASD

Intervention(s): L-DOPA versus Placebo, Social Skills Training

Status: Active, not recruiting

Enrollment (expected or actual): 56

Allocation: Randomized

Sponsor: University of California, Los Angeles

Principal Investigator: James McCracken, Principal Investigator

Completion Date (primary or actual): December 2023

CT.gov Identifier: NCT03243552

The participant in this study includes Alzheimer's disease (AD including familial AD and sporadic AD) patients, amnestic mild cognitive impairment (aMCI) patients, non-AD dementia patients and cognitively normal control. The purpose of this study is to establish the best cut-off value of cerebrospinal fluid (CSF) and blood β-amyloid (Aβ) 42/40, total tau (t-tau) , phosphorylated tau ,inflammatory factors, etc. in diagnosis of Alzheimer's disease (AD).

First Posted: August 25, 2021

Condition(s): Alzheimer's Disease

Intervention(s):

Status: Recruiting

Enrollment (expected or actual): 3200

Allocation:

Sponsor: Capital Medical University

Principal Investigator: Jianping Jia, Chief Director

Completion Date (primary or actual): September 1, 2025

CT.gov Identifier: NCT05020106

This study evaluates the relationship of endocannabinoids in saliva with inflammation and oral dysbacteriosis present in people with periodontal disease and prediabetes/type 2 diabetes

First Posted: September 15, 2023

Condition(s): PreDiabetes, Diabetes Mellitus, Type 2, Obesity, Oral Dysbiosis, Mouth Disease

Intervention(s): Observational study

Status: Not yet recruiting

Enrollment (expected or actual): 60

Allocation:

Sponsor: Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud

Principal Investigator:

Completion Date (primary or actual): June 30, 2024

CT.gov Identifier: NCT06040164

Progressive Supranuclear Palsy (PSP), Cortico-Basal Degeneration (CBD) and Multiple System Atrophy (MSA) are degenerative brain conditions for which there are currently no curative treatments. To aid the development of new treatment trials, there is a pressing need to develop better methods for diagnosing these conditions early, and to track disease progression. The PROSPECT-M-UK study will collect standardised clinical data over time. Patients will also have the option to have a brain MRI scan, eye movement exam and donate blood, skin and spinal fluid samples, with the aim to identify "biomarkers" that can improve the accuracy of early diagnosis and track the natural time course of disease. Control participants and those not meeting criteria for Parkinson's disease or other defined conditions but are considered by the investigator group to be allied syndromes or at risk states (atypical parkinsonian syndromes), will also be examined. Patients can also participate via the CBD European registry or in a one-off study assessment through the cross-sectional study, which involves completing questionnaires and a blood sample donation.

First Posted: May 20, 2016

Condition(s): Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration, Multiple System Atrophy (MSA)

Intervention(s):

Status: Recruiting

Enrollment (expected or actual): 900

Allocation:

Sponsor: University College, London

Principal Investigator:

Completion Date (primary or actual): July 2023

CT.gov Identifier: NCT02778607

Oat fibre has been shown to lower cholesterol and may have cardioprotective effects. However, whether this translates to actual cardiovascular risk reduction is unclear, as there is a lack of controlled human trials. To address this uncertainty, the investigator proposes to use established cardiovascular disease risk scores, such as those recommended by the Canadian Cardiovascular Society and other clinical practice groups, to create composite risk scores in assessing future risk. The data on oat fibre will be collected through a systematic review of controlled trials, composite cardiovascular risk scores will be calculated for each eligible study, and meta-analyses will be conducted to assess the overall effect. The findings generated by this proposed knowledge synthesis will help improve the health of consumers through informing evidence-based guidelines and improving health outcomes by educating healthcare providers and patients, stimulating industry innovation, and guiding future research design.

First Posted: December 28, 2021

Condition(s): Cardiovascular Diseases, Coronary Heart Disease

Intervention(s): Oats or Oat Fibre

Status: Active, not recruiting

Enrollment (expected or actual): 1

Allocation:

Sponsor: University of Toronto

Principal Investigator: John Sievenpiper, Associate Professor

Completion Date (primary or actual): January 30, 2022

CT.gov Identifier: NCT05171283

This study investigates the safety and combined effect of Cranberry leaves, Cranberry Berries, Alfalfa, Fenugreek, Lemon Beebrush, Urtica, Dog-rose, and Sumac on improving the glycemic profile of patients with type 2 diabetes mellitus compared to the placebo group.

First Posted: January 26, 2023

Condition(s): Type 2 Diabetes

Intervention(s): Capsules containing the combination products, Placebo capsules

Status: Not yet recruiting

Enrollment (expected or actual): 60

Allocation: Randomized

Sponsor: Tabriz University of Medical Sciences

Principal Investigator: Dr. Saeid Safiri, Principal Investigator

Completion Date (primary or actual): February 28, 2024

CT.gov Identifier: NCT05700513

In this study, the following subjects will be exposed to human rhinovirus (HRV): those with classification of mild-moderate asthma healthy control subjects. The investigators will study the kinetics of HRV-induced inflammatory and remodeling responses in a well characterized group of asthmatic subjects and compare these outcomes to those in a healthy, non-asthmatic control group.

First Posted: May 7, 2013

Condition(s): Asthma

Intervention(s): GMP-grade HRV-39, Bronchoalveolar Lavage, Methacholine Inhalation Challenge, Nasal Lavage, Nasal Scrapings, Bronchial Brushings, Lung Mucosal Biopsy, Allergen Skin Prick Testing, Venipuncture, Bronchoscopy, Spirometry

Status: Terminated

Enrollment (expected or actual): 2

Allocation: Non-Randomized

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Principal Investigator:

Completion Date (primary or actual): July 2015

CT.gov Identifier: NCT01847768

Bilateral subthalamic nucleus deep brain stimulation (B-STN DBS) is one of the most effective surgical treatments for PD patients suffering from levodopa-induced motor complications. The relatively low incidence of permanent adverse effects and the potential for neuroprotection and alteration of the natural course of PD suggest a highly favorable benefit-to-risk ratio of this procedure. Since neuroprotection is best applied early in the disease course when there are more surviving neurons, we believe that further investigation of this procedure is warranted. The proposed pilot study will provide the necessary data to substantiate the safety and tolerability of the procedure as well as provide data for the design of a full-scale, multicenter trial to investigate the hypothesis that B-STN DBS is a safe and effective treatment to slow the progression of PD.

First Posted: January 25, 2006

Condition(s): Parkinson's Disease

Intervention(s): B-STN DBS, Optimal drug therapy

Status: Completed

Enrollment (expected or actual): 37

Allocation: Randomized

Sponsor: Vanderbilt University Medical Center

Principal Investigator: David Charles, Associate Professor of Neurology

Completion Date (primary or actual): January 2012

CT.gov Identifier: NCT00282152

The purpose of this study is to explore the effects of cooked navy bean powder or rice bran consumption on the stool microbiome and metabolome of colorectal cancer survivors and healthy adults.

First Posted: August 27, 2013

Condition(s): Colorectal Cancer Control and Prevention

Intervention(s): Placebo-Control Meals and Snacks, Cooked Navy Bean Powder Meals and Snacks, Rice Bran Meals and Snacks

Status: Completed

Enrollment (expected or actual): 29

Allocation: Randomized

Sponsor: Colorado State University

Principal Investigator: Elizabeth P Ryan, Assistant Professor of Toxicology and Nutrition

Completion Date (primary or actual): December 2014

CT.gov Identifier: NCT01929122

The aim of the project is to examine whether the sources of n-3 fatty acids and fish itself differ in their effects on glucose metabolism, lipid metabolism, blood pressure, and serum inflammatory markers. Lipidomic profiles and gene expression will be used for thorough assessment of the possible clinical changes. The study will compare the effects of alpha-linolenic acid containing vegetable oil, fatty fish, lean fish and control diet. The results of this project will help to identify the optimal source of n-3 fatty acids, and reveal the significance of the components of fish other than fatty acids. These data will be useful both nationally and internationally, since highly controlled dietary interventions utilizing new methodology are scarce.

First Posted: January 15, 2013

Condition(s): Hyperglycemia

Intervention(s): Fatty fish, Lean Fish, Alpha-linolenic acid, Control

Status: Completed

Enrollment (expected or actual): 79

Allocation: Randomized

Sponsor: University of Eastern Finland

Principal Investigator:

Completion Date (primary or actual): June 2014

CT.gov Identifier: NCT01768429

This is an extension study to evaluate the long-term safety and tolerability of ABT-SLV187 in subjects with advanced Parkinson's disease.

First Posted: March 10, 2014

Condition(s): Advanced Parkinson's Disease

Intervention(s): ABT-SLV187

Status: Completed

Enrollment (expected or actual): 30

Allocation: N/A

Sponsor: AbbVie

Principal Investigator:

Completion Date (primary or actual): October 31, 2019

CT.gov Identifier: NCT02082249

Carpal tunnel syndrome (CTS) is the most common nerve compression disease and the most expensive upper-extremity work-related musculoskeletal disorder, affecting approximately 10 million people in the US. To understand the clear etiology and mechanism of carpal tunnel syndrome, the measurement of median nerve intraneural blood flow needs to be further scrutinized as the common fluctuating physiological conditions and functional hand activities might contribute to the fluctuation of the measurement and serve as measurement error. This study aims to examine how intraneural blood flow within the median nerve is affected by physiological factors (i.e., body temperature and blood pressure) and functional hand activities (i.e., typing, using a mouse, and cooking).

First Posted: September 27, 2021

Condition(s): Carpal Tunnel Syndrome, Median Nerve Injury

Intervention(s): Cooling, Heating, Exercising, Typing, Using a mouse, Cooking

Status: Completed

Enrollment (expected or actual): 20

Allocation: N/A

Sponsor: University of Southern California

Principal Investigator: Shawn Roll, Associate Professor

Completion Date (primary or actual): May 30, 2022

CT.gov Identifier: NCT05057754

Cortical plasticity plays a pivotal role in functional recovery after a stroke. Neurotransmitter release, facilitates the creation of new synapses and promotes brain plasticity. In a pilot study, will evaluate the potential benefit of drugs that increase the release of neurotransmitters in patients with first stroke.

First Posted: March 12, 2015

Condition(s): Stroke

Intervention(s): placebo, citalopram, sinemet plus

Status: Completed

Enrollment (expected or actual): 39

Allocation: Randomized

Sponsor: Hospital de Granollers

Principal Investigator:

Completion Date (primary or actual): March 2017

CT.gov Identifier: NCT02386475